Profiles

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Stage 3: Technically Confirmed Profiles

• FDG-PET/CT for Response to Cancer Therapy 2016-11-18

Stage 2: Consensus Profiles

• Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016 (Public Comment ended Feb 2017)

• Checklist: SPECT Profile Conformance

• CT Tumor Volumetry for Advanced Disease 2016-11-21b

• Checklist - CT Tumor Volumetry for Advanced Disease

Stage 1: Public Comment Profiles

Link to QIBA Public Comment Form: http://tinyurl.com/y8dy2pc2

• QIBA fMRI Profile 2017-06-19 Public Comment to open on June 19, 2017
• QIBA PET Amyloid Profile 2017-06-15 Public Comment is open until September 15, 2017
• DWI Profile 2017-04-27 Public Comment is open until July 28, 2017

Stage 1: Public Comment closed

• QIBA Profile: QIBA Profile: Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening, June 1, 2016 (Public Comment ended Sept 2016)

• QIBA Spreadsheet: Small Nodule Profile References_Accuracy. Version for Public Comment. June 1, 2016

• QIBA Spreadsheet: Small Nodule Profile References_Precision. Version for Public Comment. June 1, 2016

• DCE-MRI Quantification 2011-12-13 (Public Comment ended Feb 2012)

Statements of Endorsement

• Industry
• Clinical Sites
• Additional letters of support can be found here

See Also

• How to use QIBA Profiles
• Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
• Profile Conformance describes how sites and products claim conformance to a Profile.
• QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)

• Work Product for Review